Latest news with #GLAs
NZ Autocar
5 days ago
- Automotive
- NZ Autocar
A future Mercedes rival for Golf and ID 3 is a crossover
The third-generation GLA will become the smallest member of the Mercedes-Benz MMA-based compact car family. And it will be sold in both electric and hybrid forms. It effectively replaces the second-gen ICE powered GLA and also the EQA EV. Expect it to debut in the second half of next year. Images of the car testing in camouflage reveal that it will have a more coupé-like silhouette than today's GLA, sporting the new 'Iconic Grille' of the brand. Evidently the crossover will be bigger than previous GLAs at just over 4500mm in length, for more interior and luggage capacity. The cars it replaces are both shy of 4500mm. No interior shots are available but it will likely use the same architecture as the new CLA saloon. So a full-width display, AI-supported infotainment functions and superior materials compared with the outgoing models. A frunk is likely for the EV, unlike with the outgoing EQA. It will also come with an 800V electrical architecture for rapid charging. An entry-level model will sport a 59kWh LFP battery pack, while a longer range variant will have an 85kWh NMC battery. The latter should offer range of almost 800km. Single- or dual-motor powertrains will be available, delivering 200kW and 260kW, respectively. Further down the line, two AMG performance models with axial flux motors by subsidiary Yasa will launch in 2027. ICE versions of the GLA will use a 1.5-litre four-cylinder turbopetrol hybrid offering 100 to 140kW, mated to an eight-speed dual-clutch automatic gearbox. Production will be at the Rastatt plant in Germany where the CLA is made.
Business Insider
06-08-2025
- Health
- Business Insider
Fractyl Health announces two-year follow-up data from Revita study
Fractyl Health (GUTS) announced two-year follow-up data from the Germany Real-World Registry study that showed a single Revita procedure led to durable weight loss and improved glucose control in people with obesity and advanced T2D. These data underscore Revita's potential to provide a potent and durable non-drug alternative for patients struggling with long-term metabolic control. The Germany Real-World Registry study is a prospective, post-market, clinical follow-up study to evaluate the Revita procedure in patients with inadequately controlled T2D. Participants had a baseline HbA1c between 7%-10%, BMI of 45 kg/m, and were on at least one glucose-lowering agent. At baseline, the first nine participants with two years of follow-up had a median age of 62 years, median weight of 104 kg, and a median HbA1c of 9.6%, despite being on up to three GLAs. After a single Revita procedure, these nine participants achieved a median weight loss of 9.6% with weight decreasing from 104 kg to 97 kg at 1 year, a result that was sustained throughout 2 years. Notably, 7 of 8 participants experienced at least a 5% weight reduction, and 5 of 8 saw reductions of 10%. Only one participant, with a history of cortisone therapy known to cause weight gain, experienced modest weight gain. In parallel, median HbA1c reduced by 1.6%, from 9.6% at baseline to 7.2% at 1 year, and this improvement was sustained throughout two years, even as participants reduced or stabilized their use of GLAs. Three patients were on a GLP-1 drug at the time of study entry and were still on a GLP-1 drug through two years of follow-up. No device- or procedure-related serious adverse events have been reported to date. In this cohort, weight loss and glucose improvements began as early as one month after the Revita procedure and were sustained through two years of follow-up. These findings highlight the potential of a single Revita treatment to deliver durable weight maintenance in a real-world setting. Thirty-four participants are currently enrolled in the Germany Real-World Registry study. While the study is no longer enrolling new patients, Fractyl will continue protocol-defined follow-up of participants and share outcomes on an ongoing basis. Revita is being studied in an ongoing IDE-approved REMAIN-1 pivotal study to evaluate its potential safety and efficacy in post-GLP-1 weight maintenance. These new findings from Germany add real-world momentum to Fractyl's upcoming pivotal trial readouts, including Midpoint Cohort data from its ongoing REMAIN-1 study, which is expected in Q3 2025, and primary endpoint data from the Pivotal Cohort, anticipated in H2 2026. Together, these clinical milestones are designed to demonstrate Revita's potential to help maintain weight loss after GLP-1 discontinuation and inform its possible role in supporting durable metabolic outcomes for patients with obesity.
